Jacob Falck Hansen

Jacob joins from Novo Nordisk A/S where he has worked for 15 years, most recently as Head of Corporate Strategy supporting its Executive Management and Board of Directors.

Jacob has a deep understanding of the pharma industry across all parts of the value chain and many disease areas. He has significant experience with strategy development and execution and has been a trusted advisor to senior leadership in Novo Nordisk.

Jacob holds an MSc in Biochemistry and a PhD from the University of Copenhagen. Jacob is the author of more than 25 peer-reviewed scientific publications, including several in high-ranking journals such as Nature and Science, and the recipient of three prestigious awards for young researchers, including the Lundbeck Foundation Talent Prize.

Board Representative: DYSIS Medical, Notify Therapeutics

Board Observer: Cytoki Pharma, SNIPR Biome